IRIS Institutional Research Information System - OPENBS Open Archive UniBS

RAVAGGI, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.981
EU - Europa 2.125
AS - Asia 828
Continente sconosciuto - Info sul continente non disponibili 9
AF - Africa 8
OC - Oceania 5
SA - Sud America 5
Totale 7.961
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.910
PL - Polonia 569
CN - Cina 549
UA - Ucraina 414
DE - Germania 407
IT - Italia 241
HK - Hong Kong 170
GB - Regno Unito 155
FI - Finlandia 150
IE - Irlanda 83
CA - Canada 68
VN - Vietnam 36
FR - Francia 34
SE - Svezia 28
IN - India 27
RU - Federazione Russa 18
SG - Singapore 12
BE - Belgio 11
EU - Europa 9
KR - Corea 6
NL - Olanda 6
AU - Australia 5
TR - Turchia 5
BG - Bulgaria 4
KG - Kirghizistan 4
MU - Mauritius 4
TW - Taiwan 4
BR - Brasile 3
IR - Iran 3
LK - Sri Lanka 3
ID - Indonesia 2
MX - Messico 2
TH - Thailandia 2
AT - Austria 1
AZ - Azerbaigian 1
BD - Bangladesh 1
CL - Cile 1
CR - Costa Rica 1
EE - Estonia 1
EG - Egitto 1
HU - Ungheria 1
JP - Giappone 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MA - Marocco 1
NG - Nigeria 1
PE - Perù 1
PH - Filippine 1
PT - Portogallo 1
TN - Tunisia 1
Totale 7.961
Salva come PNG Salva come JPEG
Città #
Fairfield 744
Warsaw 568
Woodbridge 563
Houston 381
Ashburn 378
Seattle 331
Jacksonville 307
Chandler 292
Wilmington 262
Ann Arbor 256
Cambridge 249
Dearborn 161
New York 153
Hong Kong 152
Princeton 149
Helsinki 101
Nanjing 101
Dublin 83
Mcallen 83
Munich 80
Beijing 79
Brescia 62
Shanghai 44
Nanchang 41
Montréal 39
Dong Ket 36
Shenyang 36
San Diego 32
Des Moines 31
Jinan 31
Toronto 28
Hebei 26
Milan 26
Jiaxing 23
Kunming 23
Changsha 21
Tianjin 18
Los Angeles 15
Hangzhou 14
Central 13
London 13
Monmouth Junction 13
Brussels 11
Zhengzhou 11
Hefei 10
Ningbo 9
Lancaster 8
Lanzhou 8
Leawood 8
Norwalk 8
Rome 8
Taizhou 8
Verona 8
Guangzhou 7
Kilburn 7
San Francisco 7
Augusta 5
Haikou 5
San Mateo 5
Taiyuan 5
Washington 5
Bishkek 4
Cazzago San Martino 4
Fuzhou 4
Melbourne 4
Nardò 4
New Bedfont 4
Orange 4
Paris 4
Phoenix 4
Pune 4
Sofia 4
Ardabil 3
Arezzo 3
Colombo 3
Gunzenhausen 3
North 3
Nürnberg 3
Taoyuan District 3
Xian 3
Baton Rouge 2
Berlin 2
Boardman 2
Chengdu 2
Cheongju-si 2
Exeter 2
Islington 2
Lappeenranta 2
Mexico City 2
Neustadt an der Aisch 2
Newark 2
Redwood City 2
Romainville 2
Salerno 2
San Bruno 2
South San Francisco 2
Wuhan 2
Abuja 1
Almaty 1
Almere Stad 1
Totale 6.306
Salva come PNG Salva come JPEG
Nome #
Influence of maternal CD4+ levels on the predictive value of virus load mother-to-child transmission of HIV type 1 (HIV-1) 371
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues 282
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 256
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 239
Claudin3 is localized outside the tight junctions in human carcinomas 225
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery 218
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 147
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts 146
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 142
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 141
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition 140
A prognostic regulatory pathway in stage I epithelial ovarian cancer: New hints for the poor prognosis assessment 139
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 135
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 134
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 132
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients 132
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. 127
Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. 125
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 125
Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer 125
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients 125
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 124
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 121
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 119
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 118
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 116
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 113
Mammaglobin B expression in human endometrial cancer 112
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 110
DEVELOPMENT AND THERAPEUTIC EFFECT OF ADOPTIVELY TRANSFERRED T CELLS PRIMED BY TUMOR LYSATE-PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ENDOMETRIAL CANCER. 108
TUMOR-INFILTRATING LYMPHOCYTES CONTAIN HIGHER NUMBERS OF TYPE 1 CYTOKINE EXPRESSORS AND DR+ T CELLS COMPARED WITH LYMPHOCYTES FROM TUMOR DRAINING LYMPH NODES AND PERIPHERAL BLOOD IN PATIENTS WITH CANCER OF THE UTERINE CERVIX. 108
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 108
MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities. 108
Quantification of hepatitis C virus RNA by competitive amplification of RNA from denatured serum and hybridization on microtiter plates 107
The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines 106
HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. 104
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy 103
IN VITRO INDUCTION OF TUMOR-SPECIFIC HUMAN LYMPHOCYTE ANTIGEN CLASS I-RESTRICTED CD8 CYTOTOXIC T LYMPHOCYTES BY OVARIAN TUMOR ANTIGEN-PULSED AUTOLOGOUS DENDRITIC CELLS FROM PATIENTS WITH ADVANCED OVARIAN CANCER. 102
INDUCTION OF OVARIAN TUMOR-SPECIFIC CD CYTOTOXIC T LYMPHOCYTES BY ACID-ELUTED PEPTIDE-PULSED AUTOLOGOUS DENDRITIC CELLS 101
Prognostic Significance of Vascular Endothelial Growth Factor Serum Determination in Women with Ovarian Cancer 101
Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers 100
Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. 99
INCREASED LEVELS OF INTERLEUKIN-10 AND TRANSFORMING GROWTH FACTOR-BETA IN THE PLASMA AND ASCITIC FLUID OF PATIENTS WITH ADVANCED OVARIAN CANCER. 96
Genetic evolution of the hypervariable region 1 in hetpatitis C virus carriers with normal aminotransferase activities 94
LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study 93
Radiation-Enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma 88
Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship 86
PHENOTYPIC AND FUNCTIONAL ANALYSIS OF TUMOR-INFILTRATING LYMPHOCYTES COMPARED WITH TUMOR-ASSOCIATED LYMPHOCYTES FROM ASCITIC FLUID AND PERIPHERAL BLOOD LYMPHOCYTES IN PATIENTS WITH ADVANCED OVARIAN CANCER. 85
Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways 85
Claudin-7 expression in human epithelial ovarian cancer 84
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 83
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro 81
EXPRESSION PATTERN AND MOLECULAR FUNCTION OF TRASCRIPTION FACTOR FOXM1 (FORKHEAD BOX PROTEIN M1) IN EPITHELIAL OVARIAN CANCER CLINICAL SPECIMENS AND CELL LINES 81
Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. 80
HE4 and epithelial ovarian cancer : Comparison and clinical evaluation of two immunoassays and a combination algorithm 78
Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology. 75
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients 74
Claudin 7 downregulation is predictive of distant metastasis in high-grade serous carcinoma patients 71
Genome-wide study of salivary miRNAs identifies miR-423-5p as promising diagnostic and prognostic biomarker in oral squamous cell carcinoma 67
Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy With hRS7, a Humanized Anti-Trop-2 Monoclonal Antibody 65
DEVELOPMENT, CHARACTERIZATION AND DISTRIBUTION OF ADOPTIVELY TRANSFERRED PERIPHERAL BLOOD LYMPHOCYTES PRIMED BY HUMAN PAPILLOMAVIRUS 18 E7--PULSED AUTOLOGOUS DENDRITIC CELLS IN A PATIENT WITH METASTATIC ADENOCARCINOMA OF THE UTERINE CERVIX. 64
EXPRESSION OF CD56 BY HUMAN PAPILLOMAVIRUS E7-SPECIFIC CD8+ CYTOTOXIC T LYMPHOCYTES CORRELATES WITH INCREASED INTRACELLULAR PERFORIN EXPRESSION AND ENHANCED CYTOTOXICITY AGAINST HLA-A2-MATCHED CERVICAL TUMOR CELLS. 61
Serum S100A6 concentration predicts peritoneal tumor burden inmice with epithelial ovarian cancer and is associated with advanced stage in patients. 53
Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial 53
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer 52
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients 52
The claudin-low subtype of high-grade serous ovarian carcinoma exhibits stem cell features 51
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients 46
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: A retrospective study 43
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma 43
Gene expression profiling of olfactory neuroblastoma helps identify prognostic pathways and define potentially therapeutic targets 39
Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study 37
Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer 29
Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes 21
Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 21
Integrated mutational landscape analysis of uterine leiomyosarcomas 21
VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients 20
Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma 19
Functional profiles of curatively treated adenoid cystic carcinoma unveil prognostic features and potentially targetable pathways 18
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy 17
Finding the junction between claudins and endometrial carcinoma 11
HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study 8
Mammaglobin B (SCGB2A1) is a novel tumor antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy 7
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine 5
Totale 8.151
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.620
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.620
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019431 0 0 0 0 0 0 0 0 0 0 211 220
2019/20202.125 229 84 82 247 142 299 276 232 164 215 54 101
2020/20211.343 29 125 36 170 52 142 73 156 147 212 123 78
2021/2022772 93 121 10 15 5 48 49 39 32 132 64 164
2022/2023791 130 40 37 51 64 173 10 89 113 9 41 34
2023/2024850 49 32 93 86 47 221 53 49 163 51 6 0
Totale 8.151